Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-05-01

Summary

To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy

• Phase: PHASE2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Bayer; MacroGenics
• Treatments: regorafenib